Literature DB >> 2373140

Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.

M Toutoungi1, D Magnenat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373140     DOI: 10.1007/bf00278596

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.

Authors:  P Dayer; T Leemann; R Striberni
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

3.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.

Authors:  S A Ward; T Walle; U K Walle; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

Review 4.  Halothane anaesthesia and liver damage.

Authors:  J Neuberger; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

5.  Halothane hepatitis. Detection of a constitutional susceptibility factor.

Authors:  G Farrell; D Prendergast; M Murray
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

6.  Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.

Authors:  U T Meier; P Dayer; P J Malè; T Kronbach; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

7.  The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.

Authors:  E Steiner; G Alván; M Garle; J H Maguire; M Lind; S O Nilson; T Tomson; J S McClanahan; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

8.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Polymorphism of cytochrome P-450 in humans.

Authors:  F P Guengerich
Journal:  Trends Pharmacol Sci       Date:  1989-03       Impact factor: 14.819

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.